Top

Published in:

01-08-2016 | Review

What gastric cancer proteomic studies show about gastric carcinogenesis?

Authors: Mariana Ferreira Leal, Fernanda Wisnieski, Carolina de Oliveira Gigek, Leonardo Caires do Santos, Danielle Queiroz Calcagno, Rommel Rodriguez Burbano, Marilia Cardoso Smith

Published in: Tumor Biology | Issue 8/2016

Abstract

Gastric cancer is a complex, heterogeneous, and multistep disease. Over the past decades, several studies have aimed to determine the molecular factors that lead to gastric cancer development and progression. After completing the human genome sequencing, proteomic technologies have presented rapid progress. Differently from the relative static state of genome, the cell proteome is dynamic and changes in pathologic conditions. Proteomic approaches have been used to determine proteome profiles and identify differentially expressed proteins between groups of samples, such as neoplastic and nonneoplastic samples or between samples of different cancer subtypes or stages. Therefore, proteomic technologies are a useful tool toward improving the knowledge of gastric cancer molecular pathogenesis and the understanding of tumor heterogeneity. This review aimed to summarize the proteins or protein families that are frequently identified by using high-throughput screening methods and which thus may have a key role in gastric carcinogenesis. The increased knowledge of gastric carcinogenesis will clearly help in the development of new anticancer treatments. Although the studies are still in their infancy, the reviewed proteins may be useful for gastric cancer diagnosis, prognosis, and patient management.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi:10.1002/ijc.29210.PubMedCrossRef

Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107:230–6. doi:10.1002/jso.23262.PubMedCrossRef

Liu Z, Zhang J, Gao Y, Pei L, Zhou J, Gu L, et al. Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis. Clin Cancer Res. 2014;20:4598–612. doi:10.1158/1078-0432.CCR-13-3380.PubMedPubMedCentralCrossRef

Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early diagnosis and prognosis (review). Oncol Lett. 2015;9:1502–8. doi:10.3892/ol.2015.2959.PubMedPubMedCentral

Riquelme I, Saavedra K, Espinoza JA, Weber H, Garcia P, Nervi B, et al. Molecular classification of gastric cancer: towards a pathway-driven targeted therapy. Oncotarget. 2015. doi:10.18632/oncotarget.4990.

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9. doi:10.1038/nature13480.

Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, Smith MA. Epigenetic mechanisms in gastric cancer. Epigenomics. 2012;4:279–94. doi:10.2217/epi.12.22.PubMedCrossRef

Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44:570–4. doi:10.1038/ng.2246.PubMedCrossRef

Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46:573–82. doi:10.1038/ng.2983.PubMedCrossRef

10.

Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583–7. doi:10.1038/ng.2984.PubMedCrossRef

11.

Lee YS, Cho YS, Lee GK, Lee S, Kim YW, Jho S, et al. Genomic profile analysis of diffuse-type gastric cancers. Genome Biol. 2014;15:R55. doi:10.1186/gb-2014-15-4-r55.PubMedPubMedCentralCrossRef

12.

Cui J, Yin Y, Ma Q, Wang G, Olman V, Zhang Y, et al. Comprehensive characterization of the genomic alterations in human gastric cancer. Int J Cancer. 2015;137:86–95. doi:10.1002/ijc.29352.PubMedCrossRef

13.

Li H, Yu B, Li J, Su L, Yan M, Zhang J, et al. Characterization of differentially expressed genes involved in pathways associated with gastric cancer. PLoS One. 2015;10:e0125013. doi:10.1371/journal.pone.0125013.PubMedPubMedCentralCrossRef

14.

Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9. doi:10.1038/nature13480.

15.

Alvarez-Chaver P, Otero-Estevez O, Paez Dela Cadena M. Proteomics for discovery of candidate colorectal cancer biomarkers. World J Gastroenterol. 2014;20:3804–24. doi:10.3748/wjg.v20.i14.3804.PubMedPubMedCentralCrossRef

16.

Li JJ, Qi RZ, Ng GK, Xie D. Proteomics in gastric cancer research: benefits and challenges. Proteomics Clin Appl. 2009;3:185–96. doi:10.1002/prca.200800151.PubMedCrossRef

17.

Leal ML, Assumpção PP, Smith MAC, Burbano RR. Searching for gastric cancer biomarkers through proteomic approaches. J Gastroenterol Hepatol Res. 2014;3:7.

18.

Manadas B, Mendes VM, English J, Dunn MJ. Peptide fractionation in proteomics approaches. Expert Rev Proteomics. 2010;7:655–63.PubMedCrossRef

19.

Scherl A. Clinical protein mass spectrometry. Methods. 2015. doi:10.1016/j.ymeth.2015.02.015.PubMed

20.

Guo T, Fan L, Ng WH, Zhu Y, Ho M, Wan WK, et al. Multidimensional identification of tissue biomarkers of gastric cancer. J Proteome Res. 2012;11:3405–13. doi:10.1021/pr300212g.PubMedCrossRef

21.

Yang Y, Toy W, Choong LY, Hou P, Ashktorab H, Smoot DT, et al. Discovery of SLC3A2 cell membrane protein as a potential gastric cancer biomarker: implications in molecular imaging. J Proteome Res. 2012;11:5736–47. doi:10.1021/pr300555y.PubMedPubMedCentral

22.

Leal MF, Calcagno DQ, Chung J, de Freitas VM, Demachki S, Assumpcao PP, et al. Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients. Clin Exp Med. 2014. doi:10.1007/s10238-014-0299-0.

23.

Goh WQ, Ow GS, Kuznetsov VA, Chong S, Lim YP. DLAT subunit of the pyruvate dehydrogenase complex is upregulated in gastric cancer—implications in cancer therapy. Am J Transl Res. 2015;7:1140–51.PubMedPubMedCentral

24.

Gao W, Xu J, Wang F, Zhang L, Peng R, Shu Y, et al. Plasma membrane proteomic analysis of human gastric cancer tissues: revealing flotillin 1 as a marker for gastric cancer. BMC Cancer. 2015;15:367. doi:10.1186/s12885-015-1343-5.PubMedPubMedCentralCrossRef

25.

Guo T, Lee SS, Ng WH, Zhu Y, Gan CS, Zhu J, et al. Global molecular dysfunctions in gastric cancer revealed by an integrated analysis of the phosphoproteome and transcriptome. Cell Mol Life Sci. 2011;68:1983–2002. doi:10.1007/s00018-010-0545-x.PubMedCrossRef

26.

Balluff B, Rauser S, Meding S, Elsner M, Schone C, Feuchtinger A, et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol. 2011;179:2720–9. doi:10.1016/j.ajpath.2011.08.032.PubMedPubMedCentralCrossRef

27.

Porta T, Lesur A, Varesio E, Hopfgartner G. Quantification in MALDI-MS imaging: what can we learn from MALDI-selected reaction monitoring and what can we expect for imaging? Anal Bioanal Chem. 2015;407:2177–87. doi:10.1007/s00216-014-8315-5.PubMedCrossRef

28.

Lam SW, Jimenez CR, Boven E. Breast cancer classification by proteomic technologies: current state of knowledge. Cancer Treat Rev. 2014;40:129–38. doi:10.1016/j.ctrv.2013.06.006.PubMedCrossRef

29.

Langley SR, Dwyer J, Drozdov I, Yin X, Mayr M. Proteomics: from single molecules to biological pathways. Cardiovasc Res. 2013;97:612–22. doi:10.1093/cvr/cvs346.PubMedCrossRef

30.

Chahrour O, Cobice D, Malone J. Stable isotope labelling methods in mass spectrometry-based quantitative proteomics. J Pharm Biomed Anal. 2015;113:2–20. doi:10.1016/j.jpba.2015.04.013.PubMedCrossRef

31.

Melle C, Ernst G, Schimmel B, Bleul A, Kaufmann R, Hommann M, et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J Proteome Res. 2005;4:1799–804. doi:10.1021/pr050123o.PubMedCrossRef

32.

Ryu JW, Kim HJ, Lee YS, Myong NH, Hwang CH, Lee GS, et al. The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci. 2003;18:505–9.PubMedPubMedCentralCrossRef

33.

He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics. 2004;4:3276–87.PubMedCrossRef

34.

Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res. 2004;14:491–9.PubMed

35.

Wang KJ, Wang RT, Zhang JZ. Identification of tumor markers using two-dimensional electrophoresis in gastric carcinoma. World J Gastroenterol. 2004;10:2179–83.PubMedPubMedCentral

36.

Ebert MP, Kruger S, Fogeron ML, Lamer S, Chen J, Pross M, et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics. 2005;5:1693–704. doi:10.1002/pmic.200401030.PubMedCrossRef

37.

Nishigaki R, Osaki M, Hiratsuka M, Toda T, Murakami K, Jeang KT, et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics. 2005;5:3205–13.PubMedCrossRef

38.

Lim BH, Cho BI, Kim YN, Kim JW, Park ST, Lee CW. Overexpression of nicotinamide N-methyltransferase in gastric cancer tissues and its potential post-translational modification. Exp Mol Med. 2006;38:455–65. doi:10.1038/emm.2006.54.PubMedCrossRef

39.

Yoshihara T, Kadota Y, Yoshimura Y, Tatano Y, Takeuchi N, Okitsu H, et al. Proteomic alteration in gastric adenocarcinomas from Japanese patients. Mol Cancer. 2006;5:75.PubMedPubMedCentralCrossRef

40.

Cheng Y, Zhang J, Li Y, Wang Y, Gong J. Proteome analysis of human gastric cardia adenocarcinoma by laser capture microdissection. BMC Cancer. 2007;7:191.PubMedPubMedCentralCrossRef

41.

Li N, Zhang J, Liang Y, Shao J, Peng F, Sun M, et al. A controversial tumor marker: is SM22 a proper biomarker for gastric cancer cells? J Proteome Res. 2007;6:3304–12.PubMedCrossRef

42.

Zhang J, Kang B, Tan X, Bai Z, Liang Y, Xing R, et al. Comparative analysis of the protein profiles from primary gastric tumors and their adjacent regions: MAWBP could be a new protein candidate involved in gastric cancer. J Proteome Res. 2007;6:4423–32.PubMedCrossRef

43.

Lin LL, Chen CN, Lin WC, Lee PH, Chang KJ, Lai YP, et al. Annexin A4: a novel molecular marker for gastric cancer with Helicobacter pylori infection using proteomics approach. Proteomics Clin Appl. 2008;2:619–34. doi:10.1002/prca.200780088.PubMedCrossRef

44.

Liu R, Li Z, Bai S, Zhang H, Tang M, Lei Y, et al. Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics. 2009;8:70–85. doi:10.1074/mcp.M800195-MCP200.PubMedCrossRef

45.

Wu C, Luo Z, Chen X, Wu C, Yao D, Zhao P, et al. Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. Oncol Rep. 2009;21:1429–37.PubMedCrossRef

46.

Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res. 2010;9:4123–30. doi:10.1021/pr100302b.PubMedPubMedCentralCrossRef

47.

Bai Z, Ye Y, Liang B, Xu F, Zhang H, Zhang Y, et al. Proteomics-based identification of a group of apoptosis-related proteins and biomarkers in gastric cancer. Int J Oncol. 2011;38:375–83.PubMed

48.

Aquino PF, Fischer JS, Neves-Ferreira AG, Perales J, Domont GB, Araujo GD, et al. Are gastric cancer resection margin proteomic profiles more similar to those from controls or tumors? J Proteome Res. 2012;11:5836–42. doi:10.1021/pr300612x.PubMed

49.

Kocevar N, Odreman F, Vindigni A, Grazio SF, Komel R. Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers. World J Gastroenterol. 2012;18:1216–28. doi:10.3748/wjg.v18.i11.1216.PubMedPubMedCentralCrossRef

50.

Zhang ZQ, Li XJ, Liu GT, Xia Y, Zhang XY, Wen H. Identification of Annexin A1 protein expression in human gastric adenocarcinoma using proteomics and tissue microarray. World J Gastroenterol. 2013;19:7795–803. doi:10.3748/wjg.v19.i43.7795.PubMedPubMedCentralCrossRef

51.

Kikuchi S, Kaibe N, Morimoto K, Fukui H, Niwa H, Maeyama Y, et al. Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer. Gastric Cancer. 2014. doi:10.1007/s10120-014-0390-y.

52.

Kocevar N, Grazio SF, Komel R. Two-dimensional gel electrophoresis of gastric tissue in an alkaline pH range. Proteomics. 2014;14:311–21. doi:10.1002/pmic.201200574.PubMedCrossRef

53.

Liu YF, Liu QQ, Wang X, Luo CH. Clinical significance of S100A2 expression in gastric cancer. Tumour Biol. 2014;35:3731–41. doi:10.1007/s13277-013-1495-3.PubMedCrossRef

54.

Deng L, Su T, Leng A, Zhang X, Xu M, Yan L, et al. Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer. Med Oncol. 2010;27:1102–8. doi:10.1007/s12032-009-9342-5.PubMedCrossRef

55.

Cai Z, Zhao JS, Li JJ, Peng DN, Wang XY, Chen TL, et al. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol Cell Proteomics. 2010;9:2617–28.PubMedPubMedCentralCrossRef

56.

Leal MF, Chung J, Calcagno DQ, Assumpcao PP, Demachki S, da Silva ID, et al. Differential proteomic analysis of noncardia gastric cancer from individuals of northern Brazil. PLoS One. 2012;7:e42255. doi:10.1371/journal.pone.0042255.PubMedPubMedCentralCrossRef

57.

Ichikawa H, Kanda T, Kosugi S, Kawachi Y, Sasaki H, Wakai T, et al. Laser microdissection and two-dimensional difference gel electrophoresis reveal the role of a novel macrophage-capping protein in lymph node metastasis in gastric cancer. J Proteome Res. 2013;12:3780–91. doi:10.1021/pr400439m.PubMedCrossRef

58.

Jung JH, Kim HJ, Yeom J, Yoo C, Shin J, Yoo J, et al. Lowered expression of galectin-2 is associated with lymph node metastasis in gastric cancer. J Gastroenterol. 2012;47:37–48. doi:10.1007/s00535-011-0463-1.PubMedCrossRef

59.

Takikawa M, Akiyama Y, Maruyama K, Suzuki A, Liu F, Tai S, et al. Proteomic analysis of a highly metastatic gastric cancer cell line using two-dimensional differential gel electrophoresis. Oncol Rep. 2006;16:705–11.PubMed

60.

Chen YR, Juan HF, Huang HC, Huang HH, Lee YJ, Liao MY, et al. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res. 2006;5:2727–42. doi:10.1021/pr060212g.PubMedCrossRef

61.

Hou Q, Tan HT, Lim KH, Lim TK, Khoo A, Tan IB, et al. Identification and functional validation of caldesmon as a potential gastric cancer metastasis-associated protein. J Proteome Res. 2013;12:980–90. doi:10.1021/pr3010259.PubMedCrossRef

62.

Chen J, Kahne T, Rocken C, Gotze T, Yu J, Sung JJ, et al. Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. J Proteome Res. 2004;3:1009–16. doi:10.1021/pr049916l.PubMedCrossRef

63.

Jia SQ, Niu ZJ, Zhang LH, Zhong XY, Shi T, Du H, et al. Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics. J Cancer Res Clin Oncol. 2009;135:403–11. doi:10.1007/s00432-008-0474-3.PubMedCrossRef

64.

Tseng CW, Yang JC, Chen CN, Huang HC, Chuang KN, Lin CC, et al. Identification of 14-3-3beta in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics. 2011;11:2423–39. doi:10.1002/pmic.201000449.PubMedCrossRef

65.

Li K, Sun Z, Zheng J, Lu Y, Bian Y, Ye M, et al. In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer. J Proteomics. 2013;82:130–40. doi:10.1016/j.jprot.2013.02.021.PubMedCrossRef

66.

Wu C, Luo Z, Chen X, Yao D, Zhao P, Liu L, et al. Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. Oncol Rep. 2009;21:1429–37.PubMedCrossRef

67.

Lianos GD, Alexiou GA, Mangano A, Rausei S, Boni L, Dionigi G, et al. The role of heat shock proteins in cancer. Cancer Lett. 2015;360:114–8. doi:10.1016/j.canlet.2015.02.026.PubMedCrossRef

68.

Giaginis C, Daskalopoulou SS, Vgenopoulou S, Sfiniadakis I, Kouraklis G, Theocharis SE. Heat shock protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival. BMC Gastroenterol. 2009;9:14. doi:10.1186/1471-230X-9-14.PubMedPubMedCentralCrossRef

69.

Kapranos N, Kominea A, Konstantinopoulos PA, Savva S, Artelaris S, Vandoros G, et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol. 2002;128:426–32. doi:10.1007/s00432-002-0357-y.PubMedCrossRef

70.

Li XS, Xu Q, Fu XY, Luo WS. Heat shock protein 60 overexpression is associated with the progression and prognosis in gastric cancer. PLoS One. 2014;9:e107507. doi:10.1371/journal.pone.0107507.PubMedPubMedCentralCrossRef

71.

Wang J, Cui S, Zhang X, Wu Y, Tang H. High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLoS One. 2013;8:e62876. doi:10.1371/journal.pone.0062876.PubMedPubMedCentralCrossRef

72.

Zuo DS, Dai J, Bo AH, Fan J, Xiao XY. Significance of expression of heat shock protein90alpha in human gastric cancer. World J Gastroenterol. 2003;9:2616–8.PubMedPubMedCentral

73.

Banerji U. O7.6HSP90 inhibitors in the clinic: what have we learnt? Ann Oncol. 2015;26 Suppl 2:ii10-ii1. doi:10.1093/annonc/mdv085.6.

74.

Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, et al. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci. 2011;102:1388–95. doi:10.1111/j.1349-7006.2011.01944.x.PubMedCrossRef

75.

Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK, et al. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochem Pharmacol. 2013;85:1246–56. doi:10.1016/j.bcp.2013.02.003.PubMedPubMedCentralCrossRef

76.

Liu H, Lu J, Hua Y, Zhang P, Liang Z, Ruan L, et al. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Cell Death Dis. 2015;6:e1595. doi:10.1038/cddis.2014.555.PubMedPubMedCentralCrossRef

77.

Capello M, Ferri-Borgogno S, Cappello P, Novelli F. alpha-enolase: a promising therapeutic and diagnostic tumor target. Febs J. 2011;278:1064–74.PubMedCrossRef

78.

Yan GR, Xu SH, Tan ZL, Yin XF, He QY. Proteomics characterization of gastrokine 1-induced growth inhibition of gastric cancer cells. Proteomics. 2011;11:3657–64.PubMedCrossRef

79.

Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci. 2001;58:902–20.PubMedCrossRef

80.

Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.PubMed

81.

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.PubMedPubMedCentralCrossRef

82.

Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.PubMedCrossRef

83.

Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18:54–61.PubMedPubMedCentralCrossRef

84.

Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6:449–61. doi:10.1038/nrm1661.PubMedCrossRef

85.

Zhang Q, Ye Z, Yang Q, He X, Wang H, Zhao Z. Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer. World J Surg Oncol. 2012;10:103. doi:10.1186/1477-7819-10-103.PubMedPubMedCentralCrossRef

86.

Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001;21:1339–45.PubMed

87.

Sun MY, Xing RH, Gao XJ, Yu X, He HM, Gao N, et al. ANXA2 regulates the behavior of SGC-7901 cells. Asian Pac J Cancer Prev. 2013;14:6007–12.PubMedCrossRef

88.

Zhu F, Xu C, Jiang Z, Jin M, Wang L, Zeng S, et al. Nuclear localization of annexin A1 correlates with advanced disease and peritoneal dissemination in patients with gastric carcinoma. Anat Rec (Hoboken). 2010;293:1310–4. doi:10.1002/ar.21176.CrossRef

89.

Sato Y, Kumamoto K, Saito K, Okayama H, Hayase S, Kofunato Y, et al. Up-regulated Annexin A1 expression in gastrointestinal cancer is associated with cancer invasion and lymph node metastasis. Exp Ther Med. 2011;2:239–43. doi:10.3892/etm.2011.210.PubMedPubMedCentral

90.

Cheng TY, Wu MS, Lin JT, Lin MT, Shun CT, Huang HY, et al. Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway. Cancer. 2012;118:5757–67. doi:10.1002/cncr.27565.PubMedCrossRef

91.

Rossi AF, Duarte MC, Poltronieri AB, Valsechi MC, Jorge YC, de-Santi Neto D, et al. Deregulation of annexin-A1 and galectin-1 expression in precancerous gastric lesions: intestinal metaplasia and gastric ulcer. Mediators Inflamm. 2014;2014:478138. doi:10.1155/2014/478138.PubMedPubMedCentralCrossRef

92.

Jorge YC, Mataruco MM, Araujo LP, Rossi AF, de Oliveira JG, Valsechi MC, et al. Expression of annexin-A1 and galectin-1 anti-inflammatory proteins and mRNA in chronic gastritis and gastric cancer. Mediators Inflamm. 2013;2013:152860. doi:10.1155/2013/152860.PubMedPubMedCentralCrossRef

93.

Zhai JM, Sun SJ, Wang W, Zeng C. Expression of annexin A3 in gastric cancer and its correlation with proliferation and apoptosis. Asian Pac J Cancer Prev. 2014;15:3001–4.PubMedCrossRef

94.

Yu SY, Li Y, Fan LQ, Zhao Q, Tan BB, Liu Y. Impact of Annexin A3 expression in gastric cancer cells. Neoplasma. 2014;61:257–64.PubMedCrossRef

95.

Wang X, Zhang S, Zhang J, Lam E, Liu X, Sun J, et al. Annexin A6 is down-regulated through promoter methylation in gastric cancer. Am J Transl Res. 2013;5:555–62.PubMedPubMedCentral

96.

Yuan HF, Li Y, Zhao Q, Fan LQ, Tan BB, Ye WH. Expression of annexin A7 and its clinical significance in differentiation and metastasis of gastric carcinoma. Int J Clin Exp Pathol. 2014;7:6567–74.PubMedPubMedCentral

97.

Hsu PI, Huang MS, Chen HC, Hsu PN, Lai TC, Wang JL, et al. The significance of ANXA7 expression and its correlation with poor cellular differentiation and enhanced metastatic potential of gastric cancer. J Surg Oncol. 2008;97:609–14. doi:10.1002/jso.21046.PubMedCrossRef

98.

Kim J, Kim MA, Jee CD, Jung EJ, Kim WH. Reduced expression and homozygous deletion of annexin A10 in gastric carcinoma. Int J Cancer. 2009;125:1842–50. doi:10.1002/ijc.24541.PubMedCrossRef

99.

Kim JK, Kim PJ, Jung KH, Noh JH, Eun JW, Bae HJ, et al. Decreased expression of annexin A10 in gastric cancer and its overexpression in tumor cell growth suppression. Oncol Rep. 2010;24:607–12.PubMed

100.

Lu SH, Chen YL, Shun CT, Lai JN, Peng SY, Lai PL, et al. Expression and prognostic significance of gastric-specific annexin A10 in diffuse- and intestinal-type gastric carcinoma. J Gastroenterol Hepatol. 2011;26:90–7. doi:10.1111/j.1440-1746.2010.06480.x.PubMedCrossRef

101.

Martinez-Aguilar J, Clifton-Bligh R, Molloy MP. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer. 2015;15:199. doi:10.1186/s12885-015-1217-x.PubMedPubMedCentralCrossRef

102.

Moss SE, Morgan RO. The annexins. Genome Biol. 2004;5:219. doi:10.1186/gb-2004-5-4-219.PubMedPubMedCentralCrossRef

103.

Zhang Q, Zhu M, Cheng W, Xing R, Li W, Zhao M, et al. Downregulation of 425G>A variant of calcium-binding protein S100A14 associated with poor differentiation and prognosis in gastric cancer. J Cancer Res Clin Oncol. 2015;141:691–703. doi:10.1007/s00432-014-1830-0.PubMedCrossRef

104.

Zhao X, Bai Z, Wu P, Zhang Z. S100P enhances the chemosensitivity of human gastric cancer cell lines. Cancer Biomark. 2013;13:1–10. doi:10.3233/CBM-130330.PubMedCrossRef

105.

Ge F, Wang C, Wang W, Wu B. S100P predicts prognosis and drug resistance in gastric cancer. Int J Biol Markers. 2013;28:e387–92. doi:10.5301/jbm.5000034.PubMedCrossRef

106.

Luo J, Zhu Y, Yang G, Gong L, Wang B, Liu H. Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma. Diagn Cytopathol. 2011;39:752–7. doi:10.1002/dc.21461.PubMedCrossRef

107.

Zhao Y, Zhang TB, Wang Q. Clinical significance of altered S100A2 expression in gastric cancer. Oncol Rep. 2013;29:1556–62. doi:10.3892/or.2013.2236.PubMed

108.

Thijssen VL, Heusschen R, Caers J, Griffioen AW. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta. 1855;2015:235–47. doi:10.1016/j.bbcan.2015.03.003.

109.

Timoshenko AV. Towards molecular mechanisms regulating the expression of galectins in cancer cells under microenvironmental stress conditions. Cell Mol Life Sci. 2015;72:4327–40. doi:10.1007/s00018-015-2008-x.PubMedCrossRef

110.

Chen J, Tang D, Wang S, Li QG, Zhang JR, Li P, et al. High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients. Tumour Biol. 2014;35:2513–9. doi:10.1007/s13277-013-1332-8.PubMedCrossRef

111.

Chen J, Zhou SJ, Zhang Y, Zhang GQ, Zha TZ, Feng YZ, et al. Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer. World J Gastroenterol. 2013;19:2073–9. doi:10.3748/wjg.v19.i13.2073.PubMedPubMedCentralCrossRef

112.

Bektas S, Bahadir B, Ucan BH, Ozdamar SO. CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance. Pathol Oncol Res. 2010;16:569–77. doi:10.1007/s12253-010-9248-8.PubMedCrossRef

113.

Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res. 2006;26:1369–76.PubMed

114.

Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res. 1999;27:362–7.PubMedCrossRef

115.

Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, et al. Decreased galectin-3 expression in prostate cancer. Prostate. 2000;44:118–23. doi:10.1002/1097-0045(20000701)44:2<118::AID-PROS4>3.0.CO;2-U.PubMedCrossRef

116.

van den Brule FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, et al. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer. 1994;30A:1096–9.PubMedCrossRef

117.

Lotz MM, Andrews Jr CW, Korzelius CA, Lee EC, Steele Jr GD, Clarke A, et al. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci U S A. 1993;90:3466–70.PubMedPubMedCentralCrossRef

118.

Choufani G, Nagy N, Saussez S, Marchant H, Bisschop P, Burchert M, et al. The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer. 1999;86:2353–63.PubMedCrossRef

119.

Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 1996;179:43–8. doi:10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N.PubMedCrossRef

120.

Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol. 2000;40:617–47.PubMedCrossRef

121.

Tzivion G, Avruch J. 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem. 2002;277:3061–4.PubMedCrossRef

122.

van Hemert MJ, Steensma HY, van Heusden GP. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays. 2001;23:936–46.PubMedCrossRef

123.

Yaffe MB. How do 14-3-3 proteins work?—gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett. 2002;513:53–7.PubMedCrossRef

124.

Aghazadeh Y, Papadopoulos V. The role of the 14-3-3 protein family in health, disease, and drug development. Drug Discov Today. 2016;21:278–87. doi:10.1016/j.drudis.2015.09.012.PubMedCrossRef

125.

Masters SC, Subramanian RR, Truong A, Yang H, Fujii K, Zhang H, et al. Survival-promoting functions of 14-3-3 proteins. Biochem Soc Trans. 2002;30:360–5. doi:10.1042/bst0300360.PubMedCrossRef

126.

Li Z, Liu JY, Zhang JT. 14-3-3sigma, the double-edged sword of human cancers. Am J Transl Res. 2009;1:326–40.PubMedPubMedCentral

127.

Zhou WH, Tang F, Xu J, Wu X, Feng ZY, Li HG, et al. Aberrant upregulation of 14-3-3o expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer. 2011;11:397. doi:10.1186/1471-2407-11-397.PubMedPubMedCentralCrossRef

128.

Leal MF, Calcagno DQ, Demachki S, Assumpcao PP, Chammas R, Burbano RR, et al. Clinical implication of 14-3-3 epsilon expression in gastric cancer. World J Gastroenterol. 2012;18:1531–7. doi:10.3748/wjg.v18.i13.1531.PubMedPubMedCentralCrossRef

129.

Konishi H, Nakagawa T, Harano T, Mizuno K, Saito H, Masuda A, et al. Identification of frequent G(2) checkpoint impairment and a homozygous deletion of 14-3-3epsilon at 17p13.3 in small cell lung cancers. Cancer Res. 2002;62:271–6.PubMed

130.

Che XH, Chen H, Xu ZM, Shang C, Sun KL, Fu WN. 14-3-3epsilon contributes to tumour suppression in laryngeal carcinoma by affecting apoptosis and invasion. BMC Cancer. 2010;10:306.PubMedPubMedCentralCrossRef

131.

Cvekl Jr A, Zavadil J, Birshtein BK, Grotzer MA, Cvekl A. Analysis of transcripts from 17p13.3 in medulloblastoma suggests ROX/MNT as a potential tumour suppressor gene. Eur J Cancer. 2004;40:2525–32.PubMedCrossRef

132.

Khayat AS, Guimaraes AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, et al. Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol. 2009;9:55.PubMedPubMedCentralCrossRef

133.

Xing X, Chen J, Chen M. Expression of CDC25 phosphatases in human gastric cancer. Dig Dis Sci. 2008;53:949–53.PubMedCrossRef

134.

Kumagai A, Dunphy WG. Binding of 14-3-3 proteins and nuclear export control the intracellular localization of the mitotic inducer Cdc25. Genes Dev. 1999;13:1067–72.PubMedPubMedCentralCrossRef

135.

Kumagai A, Yakowec PS, Dunphy WG. 14-3-3 proteins act as negative regulators of the mitotic inducer Cdc25 in Xenopus egg extracts. Mol Biol Cell. 1998;9:345–54.PubMedPubMedCentralCrossRef

136.

Leal MF, Nascimento JL M d, da Silva CE, Vita Lamarao MF, Calcagno DQ, Khayat AS, et al. Establishment and conventional cytogenetic characterization of three gastric cancer cell lines. Cancer Genet Cytogenet. 2009;195:85–91. doi:10.1016/j.cancergencyto.2009.04.020.PubMedCrossRef

137.

Calcagno DQ, Leal MF, Taken SS, Assumpcao PP, Demachki S, Smith Mde A, et al. Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. Anticancer Res. 2005;25:4069–74.PubMed

138.

Burbano RR, Assumpcao PP, Leal MF, Calcagno DQ, Guimaraes AC, Khayat AS, et al. C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res. 2006;26:2909–14.PubMed

139.

Assumpcao PP, Ishak G, Chen ES, Takeno SS, Leal MF, Guimaraes AC, et al. Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet. 2006;169:45–9. doi:10.1016/j.cancergencyto.2006.03.019.PubMedCrossRef

140.

Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, et al. Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma. World J Gastroenterol. 2006;12:6207–11.PubMedPubMedCentralCrossRef

141.

Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR. MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol. 2008;14:5962–8.PubMedPubMedCentralCrossRef

142.

Costa Raiol LC, Figueira Silva EC, Mendes Da Fonseca D, Leal MF, Guimaraes AC, Calcagno DQ, et al. Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma. Cancer Genet Cytogenet. 2008;181:31–5. doi:10.1016/j.cancergencyto.2007.10.011.PubMedCrossRef

143.

Calcagno DQ, Guimaraes AC, Leal MF, Seabra AD, Khayat AS, Pontes TB, et al. MYC insertions in diffuse-type gastric adenocarcinoma. Anticancer Res. 2009;29:2479–83.PubMed

144.

Calcagno DQ, Leal MF, Demachki S, Araujo MT, Freitas FW, Oliveira e Souza D, et al. MYC in gastric carcinoma and intestinal metaplasia of young adults. Cancer Genet Cytogenet. 2010;202:63–6. doi:10.1016/j.cancergencyto.2010.05.020.PubMedCrossRef

145.

Calcagno DQ, Freitas VM, Leal MF, de Souza CR, Demachki S, Montenegro R, et al. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol. 2013;13:141. doi:10.1186/1471-230X-13-141.PubMedPubMedCentralCrossRef

146.

de Souza CR, Leal MF, Calcagno DQ, Costa Sozinho EK, Borges Bdo N, Montenegro RC, et al. MYC deregulation in gastric cancer and its clinicopathological implications. PLoS One. 2013;8:e64420. doi:10.1371/journal.pone.0064420.PubMedPubMedCentralCrossRef

147.

Silva TC, Leal MF, Calcagno DQ, de Souza CR, Khayat AS, dos Santos NP, et al. hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions. BMC Gastroenterol. 2012;12:85. doi:10.1186/1471-230X-12-85.PubMedPubMedCentralCrossRef

148.

da Costa JF, Leal MF, Silva TC, Andrade Junior EF, Rezende AP, Muniz JA, et al. Experimental gastric carcinogenesis in Cebus apella nonhuman primates. PLoS One. 2011;6:e21988. doi:10.1371/journal.pone.0021988.CrossRef

149.

Leal MF, Calcagno DQ, da Costa Borges JF, Silva TC, Khayat AS, Chen ES, et al. MYC, TP53, and chromosome 17 copy-number alterations in multiple gastric cancer cell lines and in their parental primary tumors. J Biomed Biotechnol. 2011;2011:631268. doi:10.1155/2011/631268.PubMedPubMedCentralCrossRef

150.

Ribeiro HF, Alcantara DF, Matos LA, Sousa JM, Leal MF, Smith MA, et al. Cytogenetic characterization and evaluation of c-MYC gene amplification in PG100, a new Brazilian gastric cancer cell line. Braz J Med Biol Res. 2010;43:717–21.PubMedCrossRef

151.

Kang X, Zhang L, Sun J, Ni Z, Ma Y, Chen X, et al. Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J Gastroenterol. 2008;43:618–25. doi:10.1007/s00535-008-2208-3.PubMedCrossRef

152.

Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 2009;273:233–42. doi:10.1016/j.canlet.2008.08.003.PubMedCrossRef

153.

Leal MF, Cirilo PD, Mazzotti TK, Calcagno DQ, Wisnieski F, Demachki S, et al. Prohibitin expression deregulation in gastric cancer is associated with the 3' untranslated region 1630 C>T polymorphism and copy number variation. PLoS One. 2014;9:e98583. doi:10.1371/journal.pone.0098583.PubMedPubMedCentralCrossRef

154.

He Q, Zhang G, Hou D, Leng A, Xu M, Peng J, et al. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep. 2011;25:237–43.PubMed

155.

Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006;103:2316–21.PubMedPubMedCentralCrossRef

Title: What gastric cancer proteomic studies show about gastric carcinogenesis?
Authors: Mariana Ferreira Leal
Fernanda Wisnieski
Carolina de Oliveira Gigek
Leonardo Caires do Santos
Danielle Queiroz Calcagno
Rommel Rodriguez Burbano
Marilia Cardoso Smith
Publication date: 01-08-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 8/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5043-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2016

MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway

Effect of Shenfu injection on immune function of mice bearing Lewis lung sarcoma with chemotherapy

The potential role of CacyBP/SIP in tumorigenesis

Transcriptomic changes associated with DKK4 overexpression in pancreatic cancer cells detected by RNA-Seq

The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition

Telomere length in peripheral leukocytes is associated with immune cell tumor infiltration and prognosis in colorectal cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer